Black Rock Inc. Dia Medica Therapeutics Inc. Transaction History

Black Rock Inc.

$4.35 Trillion
Q2 2024

A detailed history of Black Rock Inc. transactions in Dia Medica Therapeutics Inc. stock. As of the latest transaction made, Black Rock Inc. holds 105,303 shares of DMAC stock, worth $620,234. This represents 0.0% of its overall portfolio holdings.

Number of Shares

105,303

Previous 103,370 1.87%

Holding current value

$620,234

Previous $286,000 8.39%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$2.16 - $3.66 $4,175 - $7,074	1,933 Added 1.87%	105,303 $310,000
Q1 2024 May 10, 2024	SELL	$2.58 - $3.23 $3,513 - $4,399	-1,362 Reduced 1.3%	103,370 $286,000
Q4 2023 Feb 13, 2024	BUY	$2.05 - $2.99 $6,164 - $8,990	3,007 Added 2.96%	104,732 $297,000
Q3 2023 Nov 13, 2023	BUY	$2.56 - $4.4 $76,313 - $131,164	29,810 Added 41.45%	101,725 $262,000
Q2 2023 Aug 11, 2023	BUY	$1.53 - $4.4 $374 - $1,078	245 Added 0.34%	71,915 $310,000
Q1 2023 May 12, 2023	BUY	$1.32 - $1.89 $2,287 - $3,275	1,733 Added 2.48%	71,670 $109,000
Q4 2022 Feb 13, 2023	BUY	$1.13 - $1.62 $1,205 - $1,728	1,067 Added 1.55%	69,937 $110,000
Q3 2022 Nov 14, 2022	BUY	$1.2 - $2.07 $2,583 - $4,456	2,153 Added 3.23%	68,870 $85,000
Q2 2022 Aug 12, 2022	BUY	$1.86 - $2.62 $19,117 - $26,928	10,278 Added 18.21%	66,717 $135,000
Q1 2022 May 12, 2022	SELL	$2.29 - $3.88 $4,884 - $8,276	-2,133 Reduced 3.64%	56,439 $141,000
Q4 2021 Feb 10, 2022	BUY	$3.43 - $4.65 $8,924 - $12,099	2,602 Added 4.65%	58,572 $219,000
Q3 2021 Nov 09, 2021	SELL	$3.1 - $4.32 $16,395 - $22,848	-5,289 Reduced 8.63%	55,970 $225,000
Q2 2021 Aug 11, 2021	BUY	$4.45 - $9.91 $272,602 - $607,076	61,259 New	61,259 $273,000

Others Institutions Holding DMAC

# of Institutions

Shares Held

4.24M

Call Options Held

8.2K

Put Options Held

200

View Full List

About DiaMedica Therapeutics Inc.

Ticker DMAC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,443,100
Market Cap $156M
Description
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type...

More about DMAC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account